Article
Biochemistry & Molecular Biology
Maria Paulina Reyes-Mata, Mario Alberto Mireles-Ramirez, Christian Grinan-Ferre, Merce Pallas, Lenin Pavon, Jose de Jesus Guerrero-Garcia, Daniel Ortuno-Sahagun
Summary: Multiple sclerosis is a chronic disease characterized by an autoimmune attack on axonal myelin sheaths in the central nervous system. Epigenetics has been studied as a research topic in the search for biomarkers and treatment targets for this disease. This study examined epigenetic marks in Peripheral Blood Mononuclear Cells (PBMCs) from MS patients treated with IFN-beta and GA or untreated, as well as healthy controls, and found that DNA methylation decreased in treated patients and correlated with clinical variables. However, no biomarker has been identified to predict treatment response before initiation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Clinical Neurology
Tomas Kalincik, Ibrahima Diouf, Sifat Sharmin, Charles Malpas, Tim Spelman, Dana Horakova, Eva Kubala Havrdova, Maria Trojano, Guillermo Izquierdo, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Duquette, Pierre Grammond, Vilija Jokubaitis, Anneke Van der Walt, Francois Grand'Maison, Patrizia Sola, Diana Ferraro, Vahid Shaygannejad, Raed Alroughani, Raymond Hupperts, Murat Terzi, Cavit Boz, Jeannette Lechner-Scott, Eugenio Pucci, Vincent Van Pesch, Franco Granella, Roberto Bergamaschi, Daniele Spitaleri, Mark Slee, Steve Vucic, Radek Ampapa, Pamela McCombe, Cristina Ramo-Tello, Julie Prevost, Javier Olascoaga, Edgardo Cristiano, Michael Barnett, Maria Laura Saladino, Jose Luis Sanchez-Menoyo, Suzanne Hodgkinson, Csilla Rozsa, Stella Hughes, Fraser Moore, Cameron Shaw, Ernest Butler, Olga Skibina, Orla Gray, Allan Kermode, Tunde Csepany, Bhim Singhal, Neil Shuey, Imre Piroska, Bruce Taylor, Magdolna Simo, Carmen-Adella Sirbu, Attila Sas, Helmut Butzkueven
Summary: The study demonstrates that continued treatment with MS immunotherapies significantly reduces disability accrual, risk of needing a walking aid, and frequency of relapses over a 15-year period.
Article
Medicine, Research & Experimental
Paulina Maria Reyes-Mata, Argelia Esperanza Rojas-Mayorquin, Lucrecia Carrera-Quintanar, Celia Gonzalez-Castillo, Mario Alberto Mireles-Ramirez, Jose de Jesus Guerrero-Garcia, Daniel Ortuno-Sahagun
Summary: This study aimed to investigate the serum levels of Pleiotrophin (PTN) in patients with Multiple Sclerosis (MS). The results showed that PTN serum levels were significantly higher in RRMS patients compared to the healthy control group, and were associated with sex, body mass index (BMI), and IFN-beta treatment.
ARCHIVES OF MEDICAL RESEARCH
(2022)
Article
Clinical Neurology
Mathilde Lefort, Sandra Vukusic, Romain Casey, Gilles Edan, Emmanuelle Leray
Summary: Early treatment initiation has a significant impact on disability progression in patients with relapsing-remitting multiple sclerosis (RRMS), reducing the risk of disability development, particularly in older patients.
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Review
Neurosciences
Amir Valizadeh, Mohammad Reza Fattahi, Maryam Sadeghi, Mehrnush Saghab Torbati, Mohammad Ali Sahraian, Amir Reza Azimi
Summary: The study found that DMTs can reduce the number and volume of T1 hypointense lesions in MS patients, but these findings need to be interpreted cautiously due to high heterogeneity values. The results suggest that DMTs have a certain impact on the progression of the disease in MS patients.
CNS NEUROSCIENCE & THERAPEUTICS
(2022)
Article
Clinical Neurology
Martin Valis, Zbysek Pavelek, Michal Novotny, Blanka Klimova, Jana Sarlakova, Simona Haluskova, Marek Peterka, Ivana Stetkarova, Pavel Stourac, Jan Mares, Pavel Hradilek, Radek Ampapa, Marta Vachova, Eva Recmanova, Eva Meluzinova
Summary: This study analyzed the characteristics and treatment of pediatric patients with multiple sclerosis. The results showed that these patients usually start disease-modifying drug treatment at the age of 15.89, with moderate and mild relapses being common. Moreover, the first-choice treatment is similar to that of adult patients, but low efficacy or lack of tolerance may lead to treatment discontinuation in children.
FRONTIERS IN NEUROLOGY
(2022)
Article
Clinical Neurology
E. J. Ramos Gonzalez, L. J. Ramirez Jirano, D. Z. Garcia Martinez, G. G. Ortiz, L. F. Jave Suarez, C. A. Leal Cortes, O. K. Bitzer Quintero
Summary: The present study compared the effects of MLT administration with IFN-beta and GA in an EAE rat model. Results showed that IFN-beta and GA had better clinical evaluation results compared to MLT. Further research is needed to evaluate the molecular mechanisms of MLT in EAE and quantify other cytokines in different biological media to determine if MLT can be considered as an anti-inflammatory agent for regulating MS.
Article
Ophthalmology
Joanna Roskal-Walek, Michal Biskup, Magdalena Dolecka-Slusarczyk, Anita Rosolowska, Andrzej Jaroszynski, Dominik Odrobina
Summary: Susac syndrome (SS) is difficult to diagnose as its clinical triad does not typically occur concurrently, often leading to misdiagnosis as other diseases like multiple sclerosis (MS). Combination therapy with corticosteroids, intravenous immunoglobulins, and azathioprine may improve SS symptoms.
Article
Clinical Neurology
Serkan Ozakbas, Bilge Piri Cinar, Cavid Baba, Gorkem Kosehasanogullari
Summary: This study aims to assess the prevalence of NEDA-3 in people with MS treated with self-injectable DMTs at two years and 10 years. The results show that 52.4% of patients achieved NEDA-3 within the first two years, while only 18.3% of patients continued treatment at the end of 10 years. Additionally, the rate of NEDA-3 was lower in patients over the age of 35.
ACTA NEUROLOGICA SCANDINAVICA
(2022)
Article
Immunology
Airi Rump, Kristel Ratas, Tuuli Katarina Lepasepp, Jaanus Suurvali, Olli-Pekka Smolander, Katrin Gross-Paju, Toomas Toomsoo, Jean Kanellopoulos, Sirje Ruutel Boudinot
Summary: Multiple sclerosis (MS) is an inflammatory autoimmune disorder that affects the central nervous system and leads to progressive neurological disability in young adults. It reduces the patient's lifespan by about 10 years and has a higher prevalence in women than men. Early diagnosis and treatment can improve outcomes.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY
(2023)
Article
Medicine, General & Internal
Asli Tuncer, Murat Kurtuncu, Murat Terzi, Ugur Uygunoglu, Cansu Goncuoglu, Ayse Nur Yuceyar, Ozgul Ekmekci, Recai Turkoglu, Aysun Soysal, Mesrure Koseoglu, Cavit Boz, Yesim Beckmann, Omer Faruk Turan, Meltem Demirkiran, Gulsen Akman, Burcu Altunrende, Ilknur Aydin Canturk, Erkingul Birday, Abdulcemal Ozcan, Ozden Kamisli, Nazire Pinar Acar Ozen, Rabia Gokcen Gozubatik Celik, Belgin Petek Balci, Husnu Efendi, Cansu Sarikaya, Aylin Akcali, Munire Kilinc, Sibel Canbaz Kabay, Ferah Kizilay, Serhan Sevim, Gulcan Baran Gazaloglu, Caner Feyzi Demir, Ferhat Balgetir, Nefati Kiylioglu, Hande Sariahmetoglu, Cagcan Olmez, Kamil Mavi, Suha Yuksel, Nihal Isik, Sabahattin Saip, Rana Karabudak, Aksel Siva, Mefkure Eraksoy
Summary: This study compares the clinical effectiveness of switching from first-line injectable disease modifying treatments (iDMTs) to fingolimod (FNG) and switching between first-line iDMTs in patients with multiple sclerosis (MS). The results show that patients in the FNG group experienced significantly fewer relapses and a longer time to first relapse compared to the iDMT group during the postswitch period.
TURKISH JOURNAL OF MEDICAL SCIENCES
(2023)
Article
Clinical Neurology
Zbysek Pavelek, Michal Novotny, Ondrej Soucek, Jan Krejsek, Lukas Sobisek, Ilona Sejkorova, Jiri Masopust, Kamil Kuca, Martin Valis, Blanka Klimova, Pavel Stourac
Summary: The study investigated the changes of biomarkers in MS patients treated with GA and IFN, finding that both treatments have an impact on the B cell system, with IFN having a more pronounced effect.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2021)
Article
Pharmacology & Pharmacy
Niloufar Rahiman, Parvin Zamani, Leila Arabi, Seyedeh Hoda Alavizadeh, Aminreza Nikpoor, Mohammad Mashreghi, Ali Badiee, Mahmoud Reza Jaafari
Summary: The study explores the use of liposomal formulations of Glatiramer acetate (GA) to overcome the frequent administration rate required for MS therapy. The results show that liposomal GA has higher efficacy in a murine model of MS, suggesting its potential as a reliable nanomedicine-based platform for MS treatment.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2023)
Review
Clinical Neurology
Per Soelberg Sorensen
Summary: The development of antidrug antibodies is a major problem in the treatment of multiple sclerosis. Factors such as genetic predisposition and manufacturing process contaminants contribute to the immunogenicity. Neutralizing antibodies can reduce the drug's efficacy and cause safety concerns. Different therapy options have varying antibody occurrence rates and clinical impacts, and treatment decisions should be based on measurements and disease activity.
Article
Neurosciences
Dawling A. Dionisio-Santos, Berke Karaahmet, Elizabeth K. Belcher, Laura D. Owlett, Lee A. Trojanczyk, John A. Olschowka, M. Kerry O'Banion
Summary: The study found that subcutaneous administration of glatiramer acetate (GA) improved behavioral performance, decreased Aβ plaques, and increased microglia complexity in 3xTg AD mice. There were subtle changes in the microglial transcriptome, with an upregulation of Dcstamp.
FRONTIERS IN NEUROSCIENCE
(2021)
Article
Dermatology
D. M. W. Balak, S. Fallah-Arani, C. M. Venema, H. A. M. Neumann, H. B. Thio
BRITISH JOURNAL OF DERMATOLOGY
(2015)
Article
Dermatology
Raphael Lijnen, Elsemieke Otters, Deepak Balak, Bing Thio
JOURNAL OF DERMATOLOGICAL TREATMENT
(2016)
Article
Dermatology
Enes Hajdarbegovic, Annemieke Bloem, Deepak Balak, Bing Thio, Tamar Nijsten
INDIAN JOURNAL OF DERMATOLOGY
(2015)
Review
Dermatology
D. M. W. Balak, S. Fallah Arani, E. Hajdarbegovic, C. A. F. Hagemans, W. M. Bramer, H. B. Thio, H. A. M. Neumann
BRITISH JOURNAL OF DERMATOLOGY
(2016)
Review
Dermatology
Deepak M. W. Balak, Sascha Gerdes, Aurora Parodi, Laura Salgado-Boquete
DERMATOLOGY AND THERAPY
(2020)
Letter
Dermatology
B. D. vanRhijn, S. vanRuth, D. M. W. Balak
CLINICAL AND EXPERIMENTAL DERMATOLOGY
(2021)
Editorial Material
Dermatology
D. M. W. Balak, E. Hajdarbegovic
BRITISH JOURNAL OF DERMATOLOGY
(2022)
Editorial Material
Dermatology
Deepak M. W. Balak, Lourdes M. Perez-Chada, Lisa N. Guo, Carol Mita, April W. Armstrong, Stacie J. Bell, George C. Gondo, Wilson Liao, Joseph F. Merola
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2022)
Editorial Material
Dermatology
Deepak M. W. Balak, Jo Lambert
BRITISH JOURNAL OF DERMATOLOGY
(2022)
Review
Dermatology
D. M. W. Balak, L. M. Perez-Chada, L. N. Guo, C. Mita, A. W. Armstrong, S. J. Bell, G. C. Gondo, W. Liao, J. F. Merola
Summary: This systematic literature review identified various definitions of psoriasis remission and cure. Most definitions used Psoriasis Area and Severity Index (PASI) endpoints and descriptive endpoints related to 'skin clearance'. Few definitions specified time-frame, on/off treatment, or other psoriasis-related disease domains. While there is no cure, some studies used similar endpoints to define psoriasis cure. These findings will contribute to the development of consensus-based definitions for psoriasis remission.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2022)
Editorial Material
Dermatology
Deepak M. W. Balak, Robert Rissmann
BRITISH JOURNAL OF DERMATOLOGY
(2022)
Article
Dermatology
Niels Timo Hilhorst, Elfie Deprez, Deepak Mukesh Wieshwaykumar Balak, Nanja Van Geel, Jan Gutermuth, Isabelle Hoorens, Jo Lydie Wilfried Lambert
Summary: This study aims to develop an actionable value-based outcome set (VOS) for evaluating psoriasis care. Through four phases of a mixed method approach, the study identified the outcomes deemed important by patients and selected suitable instruments to measure these outcomes. This VOS allows for the evaluation and improvement of current care processes, increasing value for patients.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Letter
Medicine, General & Internal
Deepak Balak, Enes Hajdarbegovic
NEW ENGLAND JOURNAL OF MEDICINE
(2016)
Letter
Medicine, General & Internal
Deepak Balak, Enes Hajdarbegovic
NEW ENGLAND JOURNAL OF MEDICINE
(2015)
Review
Dermatology
Deepak M. W. Balak
PSORIASIS-TARGETS AND THERAPY
(2015)